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A b s t r a c t
Background: In the era of combination antiretroviral therapy (cART), life expectancy of HIV-infected patients is the same as 
that of the general population, resulting in increasing prevalence of cardiovascular disease in this patient group.
Aim: To assess the prevalence of endothelial dysfunction in HIV-infected patients and to identify factors which affect endo-
thelial function and arterial stiffness.
Methods: Thirty-seven adult HIV-infected patients, regardless of the fact and the type of cART, were enrolled into the study. 
In patient, reactive hyperaemia peripheral arterial tonometry assessment was performed using the Endo-PAT2000 device 
(ITAMAR®). This method allows evaluation of endothelial function ant arterial stiffness.
Results: Final analysis included 37 patients (median age 38 years, range 32–45 years), including 89.2% men. Endothelial dys-
function was found in 13 (35.1%) HIV-infected patients. We found no differences in demographic and clinical characteristics, 
laboratory data, and cardiovascular drug therapy between patients with or without endothelial dysfunction, except for platelet 
count which was higher in patients with endothelial dysfunction (174 [119–193] × 103/mm3 vs. 222 [168–266] × 103/mm3, 
p = 0.03). No demographic or clinical variables were identified as predictors of endothelial dysfunction in HIV-infected 
patients. In addition, no association was found between factors related to HIV infection, chronic drug therapy and the risk of 
endothelial dysfunction. Statistically significant correlations were found between arterial stiffness and age (rs = 0.53, p < 0.001), 
red blood cell count (rs = –0.39, p = 0.018), and platelet count (rs = 0.42, p = 0.009). CD4+ and CD8+ lymphocyte 
count and viral load were similar in patients with or without endothelial dysfunction. Arterial stiffness was significantly higher 
in patients with higher viral load (rs = –0.39, p = 0.0018) and in those with established AIDS (9.5 [1.0–16.0] vs. –5 [–10–5], 
p = 0.009). cART had no effect on endothelial dysfunction, while arterial stiffness was higher in patients treated with cART 
(10 [0–15] vs. –5 [–10–3], p = 0.014).
Conclusions: Endothelial dysfunction is common in HIV-infected patients. In general, none of the analysed factors had an 
effect on endothelial function but cART had a negative effect on arterial stiffness.
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INTRODUCTION
Human immunodeficiency virus (HIV) infection and sub-
sequent acquired immune deficiency syndrome (AIDS) are 
a pandemic of the 21st century. The number of HIV-infected 
worldwide has been estimated at about 34 million. In Poland, 
about 27,000 people are infected with HIV [1]. With modern 
antiretroviral therapy, early diagnosis, and prompt treatment, 
life expectancy of HIV-infected subjects does not differ sig-
nificantly from that of the general population [2]. As a result, 
concomitant, mostly age-related conditions become more 
common in these patients. Cardiovascular (CV) disease is the 
most common cause of death among HIV-infected subjects 
receiving antiretroviral therapy [3, 4]. For this reason, iden-
tification of subclinical changes in the CV system, including 
endothelial dysfunction and increased arterial stiffness, may 
be important for prevention and monitoring of CV disease.
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Endothelial dysfunction is an early marker of coronary 
artery disease and peripheral arterial disease [5]. As endothe-
lial dysfunction is reversible, its early identification may be of 
major prognostic and therapeutic importance [6]. Endothe-
lial dysfunction is not limited to coronary vessels, where it 
is technically difficult to assess, but may be also measured 
in a clinically useful way in peripheral vessels [7, 8]. Reac-
tive hyperaemia peripheral arterial tonometry (RH-PAT) is 
a non-invasive technique allowing functional evaluation of 
peripheral microcirculation vessels by measuring changes in 
tissue tone during reactive hyperaemia [9, 10]. Patients with 
endothelial dysfunction in the coronary microcirculation were 
shown to be characterised by low peripheral hyperaemic 
response compared to subjects with normally functioning 
coronary endothelium [11].
In addition to functional changes, vascular remodelling 
may also be an indicator of preclinical changes in coronary and 
peripheral arteries. Previous studies showed that arterial stiffness 
is an independent risk factor for CV events and correlates with 
all-cause mortality [12]. Measurement of the augmentation 
index (AI) is an indirect method to evaluate arterial stiffness.
It was shown that HIV infection is associated with in-
creased levels of inflammatory interleukins, which correlate 
with higher levels of von Willebrand factor and tissue plas-
minogen activator [13]. These are biochemical indicators of 
endothelial damage in this patient group. The role of nitric 
oxide (NO), a factor exerting a major effect on endothelial 
function, has been discussed in multiple papers [14]. HIV 
proteins reduce endothelial NO synthase level and decrease 
arterial elasticity, as shown in porcine models [15]. Viral 
gp120 glycoprotein induces endothelial damage by stimulat-
ing macrophages to produce NO [16].
The aim of this study was to evaluate the prevalence of 
endothelial dysfunction and arterial stiffness and the effect 
of antiretroviral therapy on endothelial function and arterial 
stiffness, and thus on CV risk in HIV-infected patients. 
METHODS
Study group
We studied 37 adult patients with the diagnosis of HIV in-
fection. Assessment of endothelial function and arterial stiff-
ness was from January 2011 till November 2013. Exclusion 
criteria included pregnancy and lactation women, previous 
combination antiretroviral therapy (cART) interrupted less 
than 6 months prior to study inclusion, and neoplasms un-
related to HIV infection. All patients gave written informed 
consent for participation in the study. The study protocol 
was approved by the bioethics committee at the Medical 
University of Warsaw.
Clinical evaluation and laboratory testing
Each patient underwent history taking and physical examina-
tion within 7 days prior to evaluation of endothelial function 
and arterial stiffness. During physical examination, particular 
attention was paid to evaluation of CV risk factors, including 
body mass index and blood pressure. At the same time, blood 
samples were taken for laboratory testing. Laboratory tests 
included complete blood count with quantitative evaluation 
of CD4+ and CD8+ cells, number of viral copies, serum 
creatinine, bilirubin, alanine and aspartate aminotransferase, 
gammaglutamyltransferase, C-reactive protein, and D-dimer 
levels, and lipid profile.
Combined antiretroviral therapy  
and patient monitoring
Decisions to initiate or continue cART were made based on 
the Polish AIDS Society recommendations [17], taking into 
account history, physical examination, and laboratory test 
findings. Other factors taken into account when making deci-
sions regarding the choice of therapy included family situation, 
occupation, planned pregnancy, bone disease, HIV-associated 
nephropathy, liver dysfunction associated with hepatitis B 
and/or C virus infection, and psychiatric disease.
Evaluation of endothelial function  
and arterial stiffness
In each patient, RH-PAT assessment was performed using 
the Endo-PAT2000 device (ITAMAR®). The device allows 
non-invasive evaluation of endothelial function and indirect 
assessment of vascular stiffness. Its mechanism of action is 
based on endothelium-dependent arterial response to 5-min 
brachial artery occlusion. Temporary upper limb ischaemia 
results in a subsequent increase in blood flow within the 
evaluated vascular bed. This response is based on endotheli-
um-dependent vasodilatation in reaction to a local decrease 
in partial oxygen tension and increase in potassium ion 
concentration. In these circumstances, endothelium releases 
local factors that cause arterial smooth muscle relaxation. 
Peripheral Arterial Tonometry (PAT®) is a patented technology 
allowing non-invasive measurements of changes in the arte-
rial tone within peripheral vascular beds. The non-invasive 
Endo-PAT2000 system includes a pair of plethysmographic 
sensors that impart a uniform pressure field to distal two 
thirds of the fingers including their tips. To standardise results, 
measurements in all patients were performed in a sitting posi-
tion after at least 15 min of rest, allowing stabilisation of the 
CV system and adjustment to the ambient temperature. In all 
cases, patient’s hand were supported at the heart level. After 
placing sensors connected to the Endo-PAT2000 device on 
index fingers of both hands and a sphygmomanometer cuff 
on one arm, a baseline measurement was performed. Brachial 
artery flow was then occluded for 5 min by inflating the cuff. 
Following this period, pressure was released and further PAT 
measurements were made. The duration of a single examina-
tion was about 15 min. The degree of arterial tone changes in 
response to ischaemia was expressed as the reactive hyper-
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aemia index (RHI). Normal endothelial function was defined 
as RHI > 1.67. This cutoff value was suggested by the device 
manufacturer based on previous studies [9, 18]. Baseline 
pressure waveform obtained by PAT was used to calculate 
AI using the height of two systolic waveform peaks. Due to 
a significant effect of heart rate on AI, AI values were cor-
rected for heart rate using an arbitrarily defined reference 
heart rate of 75 bpm, commonly used in other studies that 
evaluated arterial stiffness [12]. Endothelium-independent 
arterial response to transient ischaemia was not evaluated in 
the present study.
Statistical analysis
Qualitative variables were reported as percentages and in 
some cases also as absolute values. All quantitative variables 
were reported as medians and interquartile ranges. The exact 
Fisher test and the Mann-Whitney U test were used to evaluate 
between-group differences in qualitative and quantitative vari-
ables, respectively. Correlations between quantitative variables 
were evaluated using the Spearman correlation coefficient. 
Univariate logistic regression analysis was used to determine 
the odds ratio of endothelial dysfunction. P < 0.05 was 
considered statistically significant. All statistical analyses were 
performed using the SAS software, version 9.2.
RESULTS
Our final analysis included 37 patients. Median age was 
38 years (range 32–45 years), and men comprised 89.2% 
of the study group. Endothelial dysfunction was found in 
13 (35.1%) HIV-infected subjects. No significant differences 
were found between subjects with or without endothelial 
dysfunction in regard to demographic and clinical data, 
laboratory test results, and use of cardiac medication, except 
for platelet count that was significantly lower in subjects with 
endothelial dysfunction compared to those without endothe-
lial dysfunction (174 [119–193] × 103/mm3 vs. 222 [168– 
–266] × 103/mm3, p = 0.03). Among patients with endothelial 
dysfunction, platelet count < 150 × 103/mm3 was found in 
31% of subjects, compared to 17% among patients without 
endothelial dysfunction. A trend for higher heart rate and 
higher triglyceride levels was also noted among patients with 
endothelial dysfunction. Detailed comparison of patients with 
and without endothelial dysfunction is shown in Table 1. None 
of the demographic and clinical parameters was an independ-
ent predictor of endothelial dysfunction among HIV-infected 
patients. Similarly, we did not find an association between 
factors related to HIV infection and chronic drug therapy and 
the risk of endothelial dysfunction. These data are shown in 
Table 2. Of all demographic, clinical, and laboratory data, 
a significant association was found between arterial stiffness 
and patient age (rs = 0.53, p < 0.001), red blood cell count 
(rs = –0.39, p = 0.018), and platelet count (rs = 0.42, 
p = 0.009). In addition, a trend was noted between serum 
high density lipoprotein cholesterol level and arterial stiffness 
(rs = –0.36, p =0.08). 
Number of CD4+ and CD8+ cells  
and the number of viral copies
Our findings indicate no significant association between the 
number and percentage proportions of CD4+ and CD8+ 
cells and endothelial dysfunction. Similarly, the number of 
viral copies did not differ between patients with and without 
endothelial dysfunction. Detailed data are shown in Ta-
ble 3. Arterial stiffness was found to be inversely proportional 
to the number of viral copies in individual patients (rs = –0.39, 
p < 0.01). No significant association was found between 
arterial stiffness and the number and percentage proportions 
of CD4+ and CD8+ cells.
Combination antiretroviral therapy
Antiretroviral therapy was used in 20 (54.1%) patients. The 
most commonly used drugs were nucleoside reverse tran-
scriptase inhibitors. No significant association was found 
between cART and endothelial dysfunction. The rates of par-
ticular drug class use in patients with and without endothelial 
dysfunction are shown in Table 4. In contrast, we found an 
association between cART and arterial stiffness. Compared 
to patients not receiving cART, those on cART were charac-
terised by higher arterial stiffness (10 [0–15] vs. –5 [–10–3], 
p = 0.014). Higher arterial stiffness was noted in patients 
treated with nucleoside reverse transcriptase inhibitors and 
protease inhibitors. Detailed data are shown in Table 5.
DISCUSSION
Our findings indicate that endothelial dysfunction is relatively 
common among HIV-infected patients. Although large studies 
evaluating endothelial dysfunction in healthy young adults 
are lacking, available data indicate that the prevalence of 
endothelial dysfunction in this population is less than 25% 
[19, 20]. We were unable to identify demographic, clinical, 
or laboratory factors that would clearly indicate an increased 
risk of endothelial dysfunction. In addition, no factors identi-
fied those HIV-infected patients in whom increased arterial 
stiffness would be more prevalent.
HIV infection and endothelial dysfunction
Previous studies showed that HIV infection is associated 
with endothelial dysfunction. Solages et al. [21] evaluated 
flow mediated dilatation (FMD) in the brachial artery and 
found a higher degree of endothelial dysfunction among 
HIV-infected patients compared to the control group. Defining 
normal FMD as 7%, that study showed that the prevalence 
of endothelial dysfunction among HIV-infected patients was 
nearly 50%, higher than in our study. However, our patients 
were younger and had less concomitant conditions that ad-
versely affect the endothelium. A high degree of endothelial 
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dysfunction (n = 13)
No endothelial  
dysfunction (n = 24)
P
Endothelial function and arterial stiffness
Reactive hyperaemia index 1.90 (1.57–2.50) 1.47 (1.34–1.57) 2.22 (1.93–2.80) < 0.0001
AI@75 2 (–5–11) 1 (–5–4) 6 (–5–15) 0.40
Demographic data
Men 89.2% 84.6% 917% 0.60
Age [years] 38 (32–45) 36 (32–43) 39 (31–46) 0.58
Clinical data
Body mass index [kg/m2] 22.8 (21.0–26.0) 23.0 (22.0–26.0) 22.8 (20.6–25.9) 0.47
SBP [mm Hg] 125 (110–140) 134 (110–140) 120 (115–135) 0.58
DBP [mm Hg] 80 (70–80) 80 (70–90) 80 (70–80) 0.53
Heart rate [bpm] 75 (70–90) 80 (73–94) 74 (68–82) 0.09
Smoking 56.8% 61.5% 54.2% 1.0
Atrial fibrillation 0.0% 0.0% 0.0% 1.0
Hypertension 5.4% 7.7% 4.2% 1.0
Diabetes 0.0% 0.0% 0.0% 1.0
History of MI 0.0% 0.0% 0.0% 1.0
History of stroke 0.0% 0.0% 0.0% 1.0
HBV infection 8.1% 15.4% 4.2% 0.27
Previous HBV infection 18.9% 15.4% 20.8% 1.00
HCV infection 21.6% 30.8% 16.7% 0.41
Laboratory tests
RBC [106/mm3] 4.46 (3.79–5.03) 4.46 (3.94–5.15) 4.50 (3.77–5.02) 0.75
Haemoglobin [g/dL] 14.3 (13.2–15.3) 14.0 (12.6–15.3) 14.3 (13.3–15.3) 0.80
Platelets [103/mm3] 194 (160–231) 174 (119–193) 222 (168–266) 0.03
WBC [103/mm3] 5.5 (4.9–7.4) 5.8 (4.8–7.7) 5.5 (5.0–7.2) 0.82
Serum creatinine [mg/dL] 0.82 (0.72–0.94) 0.77 (0.68–0.92) 0.82 (0.76–0.96) 0.34
Serum bilirubin [mg/dL] 0.69 (0.57–1.18) 0.78 (0.61–1.91) 0.66 (0.55–1.18) 0.56
AlAT [U/L] 34 (25–51) 39 (24–68) 31 (25–40) 0.35
AspAT [U/L] 27 (23–52) 52 (23–81) 26 (23–36) 0.20
GGTP [U/L] 34 (25–59) 59 (25–70) 29 (22–44) 0.13
C-reactive protein [mg/L] 4.5 (< 1–10) 5 (4–8) 4 (< 1–14) 0.98
D-dimer [mg/L] 405 (193–821) 592 (352–1022) 396 (153–726) 0.49
Total cholesterol [mg/dL] 172.5 (149.0–206.0) 177.9 (157.5–205.4) 168.2 (146.3–206.0) 0.37
Triglycerides [mg/dL] 121.2 (89.4–212.4) 164.6 (102.2–288.1) 120.4 (82.3–176.1) 0.09
HDL cholesterol [mg/dL] 44.7 (32.7–53.5) 48.3 (28.9–55.4) 43.7 (36.0–49.9) 0.93
LDL cholesterol [mg/dL] 103.2 (72.8–125.9) 91.0 (68.9–127.1) 105.3 (74.7–125.7) 0.92
Chronic drug therapy
Beta-blocker 8.1% 7.7% 8.3% 1.0
ACE inhibitor 5.4% 7.7% 4.2% 1.0
Angiotensin receptor antagonist 2.7% 0.0% 4.2% 1.0
Statin 8.1% 0.0% 12.5% 0.53
Diuretic 2.7% 7.7% 0.0% 0.35
Acetyl salicylic acid 2.7% 0.0% 4.2% 1.0
P2Y12 inhibitor 0.0% 0.0% 0.0% 1.0
Calcium antagonist 0.0% 0.0% 0.0% 1.0
AI@75— augmentation index standardised for a heart rate of 75 bpm; SBP — systolic blood pressure; DBP — diastolic blood pressure; MI —  
myocardial infarction; HBV — hepatitis B virus; HCV — hepatitis C virus; RBC — red blood cells; WBC — white blood cells; AlAT — alanine amino-
transferase; AspAT — aspartate aminotransferase; GGTP — gammaglutamyltransferase; HDL — high density lipoprotein; LDL — low density 
lipoprotein; ACE — angiotensin-converting enzyme
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recently introduced into the clinical practice, no studies are 
available that would use it to evaluate endothelial function 
in HIV-infected patients. A significant effect of low platelet 
count on endothelial function is also of interest. Low platelet 
count is a typical feature of HIV infection. As indicated by 
Torre and Pugliese [23], similar pathogenetic mechanisms may 
be responsible for both low platelet count and endothelial 
dysfunction in HIV-infected patients.
Severity of HIV infection and disturbances  
of endothelial function and arterial structure
Our study did not show a significant association between 
the number and percentage of CD4+ and CD8+ cells and 
the number of viral copies (i.e., viral load) and endothelial 
dysfunction. An earlier study showed that the number of viral 
copies may have a negative effect on endothelial function [24]. 
That study was, however, performed in patients who at least 
30 viral copies per mL, while in our study, had 15 patients 
had viral load below the limit of detection, i.e. 40 copies 
per mL. This might have affected the observed lack of asso-
ciation between the number of viral copies and endothelial 
function in the present study. On the other hand, Dube et al. 
[25] found no significant association between the number of 
viral copies and endothelial function and also obtained similar 
results in regard to the number of CD4+ cells. These data 
are consistent with our findings, indicating that neither the 
number of viral copies nor the number of CD4+ cells were 
predictors of endothelial dysfunction. Both these parameters 
also had no effect on arterial stiffness, as shown in a study in 
261 HIV-infected patients [26]. Of note, despite no effect of 
the number of CD4+ cells determined at the time of arterial 
stiffness testing, the lowest number of CD4+ cells found dur-
ing the patient’s lifetime was indeed identified as a predictor 
of increased arterial stiffness. However, we did not analyse 
such data in our study, and thus we are unable to provide any 
further interpretation of that particular finding.
Combination antiretroviral therapy and  
endothelial dysfunction and arterial stiffness
Our analysis showed no significant association between cART 
and endothelial dysfunction. Both the use of any cART and 
the use of specific drug classes had no effect on endothelial 
function. These findings are partially consistent with the results 
of previous studies. Some of them showed no association 
between either the fact or duration of cART, while others 
indicated a negative effect of cART, particularly using protease 
inhibitors, on endothelial function [25, 27]. It is also of inter-
est that levels of circulating biomarkers of endothelial injury 
decrease following initiation of cART, which may indicate its 
beneficial role in preventing endothelial dysfunction [28]. 
Previous studies showed a significant negative association 
between the degree of arterial stiffness and the use of cART, 
particularly with nucleoside and non-nucleoside reverse tran-
Table 2. Univariate analysis




Male gender 0.50 (0.06–4.04) 0.52
Age [years] 0.97 (0.91–1.04) 0.36
Body max index [kg/m2] 1.01 (0.85–1.20) 0.91
Systolic blood pressure [mm Hg] 1.01 (0.97–1.05) 0.56
Diastolic blood pressure [mm Hg] 1.03 (0.97–1.09) 0.40
Heart rate [bpm] 1.06 (0.99–1.12) 0.08
Smoking 1.35 (0.34–5.36) 0.67
Hypertension 1.92 (0.11–33.41) 0.66
HBV infection 4.18 (0.34–51.24) 0.26
Previous HBV infection 0.69 (0.68–4.18) 0.69
HCV infection 2.22 (0.45–10.94) 0.32
AI@75 0.96 (0.91–1.02) 0.20
CD4+ cells [1/mm3] 1.00 (0.99–1.01) 0.96
Percentage of CD4+ cells [%] 1.00 (0.96–1.03) 0.80
CD8+ cells [1/mm3] 1.00 (0.99–1.01) 0.70
Percentage of CD8+ cells [%] 1.01 (0.97–1.05) 0.80
Number of viral copies [1/mm3] 1.00 (1.00–1.00) 0.53
Total cholesterol [mg/dL] 1.01 (0.99–1.03) 0.25
Triglycerides [mg/dL] 1.01 (1.00–1.02) 0.06
HDL cholesterol [mg/dL] 1.00 (0.94–1.06) 0.99
LDL cholesterol [mg/dL] 1.00 (0.97–1.03) 0.99
Antiretroviral therapy 0.61 (0.16–2.38) 0.48
Nucleoside reverse  
transcriptase inhibitors 
0.53 (0.13–2.09) 0.36
Non-nucleoside reverse  
transcriptase inhibitors
0.90 (0.18–4.40) 0.90
Protease inhibitors 0.42 (0.09–1.93) 0.26
Integrase inhibitors 1.92 (0.11–33.41) 0.66




HBV — hepatitis B virus; HCV — hepatitis C virus; AI@75 — augmen-
tation index standardised for a heart rate of 75 bpm; HDL — high 
density lipoprotein; LDL — low density lipoprotein
dysfunction is also seen in patients on chronic cART [22]. It was 
shown that among patients receiving cART for at least 2 years, 
abnormal FMD indicating endothelial dysfunction may be 
present in more than 50% of subjects. Of note, the method 
to evaluate endothelial dysfunction in the above mentioned 
studies differed from the currently used approach. FMD 
measurements are a subjective method that mostly evaluates 
endothelial function in the macrocirculation. The objective 
RH-PAT approach used in our study mostly evaluates small 
vessel endothelial function. As this method has been relatively 
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dysfunction (n = 13)
No endothelial  
dysfunction (n = 24)
P
CD4+ cells [1/mm3] 366 (135–546) 366 (168–509) 372 (123–561) 0.91
Percentage of CD4+ cells [%] 30 (30–44) 27.0 (20.0–44.0) 32.0 (18.0–42.5) 0.89
CD8+ cells [1/mm3] 692 (522–1024) 733 (525–1024) 659 (449–978) 0.68
Percentage of CD8+ cells [%] 66 (58–76) 66.0 (55.0–76.0) 67.5 (58.5–77.0) 1.0
Number of viral copies [1/mm3] 758 (< 40–35997) 7601 (154–94328) 377 (< 40–24739) 0.11




dysfunction (n = 13)
No endothelial  
dysfunction (n = 24)
P
Antiretroviral therapy 54.1% 46.2% 58.3% 0.51
Nucleoside reverse transcriptase inhibitors 48.6% 38.5% 54.2% 0.49
Non-nucleoside reverse transcriptase inhibitors 24.3% 23.1% 25.0% 1.00
Protease inhibitors 35.1% 23.1% 41.7% 0.31
Integrase inhibitors 5.4% 7.7% 4.2% 1.00
Table 5. Effect of combination antiretroviral therapy on arterial stiffness as evaluated based on augmentation index standardised 
to a heart rate of 75 bpm (AI@75)
AI@75 in patients  
receiving a given drug
AI@75 in patients  
not receiving a given drug 
P
Antiretroviral therapy 10 (0–15); n = 20 –5 (–10–3); n = 17 0.014
Nucleoside reverse transcriptase inhibitors 11 (1–16); n = 18 –5 (–10–4); n = 19 0.006
Non-nucleoside reverse transcriptase inhibitors 1 (–5–11); n = 9 3 (–6–12); n = 28 0.77
Protease inhibitors 11 (4–16); n = 13 –3 (–8–6); n = 24 0.017
Integrase inhibitors 1 (–9–11); n = 2 2 (–5–13); n = 35 0.82
scriptase inhibitors, while no such association could be clearly 
shown for protease inhibitors [25, 29]. Our conclusions are 
only partially consistent with previously reported results. The 
observed association between higher viral load and reduced 
arterial stiffness should be likely interpreted in the context 
of the use of cART, as it seems that not the low number of 
viral copies but the use of cART itself has a negative effect 
on arterial stiffness.
Limitations of the study
One limitation of the present study is a small number of 
participants. Assessment of endothelial function was offered 
to all patients presenting about every 6 months for follow-up 
appointments at the Department of Hepatology and Acquired 
Immune Deficits, Medical University of Warsaw. The studied 
group was heterogeneous in regard to the types and dura-
tion of antiretroviral therapy, which certainly rendered our 
findings more difficult to interpret, particularly in regard to 
the effect of cART on endothelial function and arterial stif-
fness. In our study, we used an indirect method to evaluate 
arterial stiffness based on AI measurements. It is considered 
less precise than the current reference method of pulse wave 
velocity measurements.
CONCLUSIONS
Our study showed that endothelial dysfunction is common 
among HIV-infected patients. However, we were unable to 
identify factors directly affecting endothelial dysfunction in this 
patient group. Of the evaluated factors, cART was found to 
have a possible effect resulting in increased arterial stiffness. In 
view of a pilot nature of the present study, we will continue 
to follow up the included patients and recruit new ones. This 
may help in identification of parameters that might indicate 
an increased CV risk in these patients.
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Ocena funkcji śródbłonka i sztywności naczyń  
u pacjentów zakażonych HIV: badanie pilotażowe
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S t r e s z c z e n i e
Wstęp: Dzięki stosowaniu kompleksowej terapii antyretrowirusowej (cART, combined antiretroviral therapy) długość życia 
pacjentów zakażonych HIV nie różni się istotnie od populacji ogólnej. Oznacza to, że wśród tych osób wzrasta częstość wy-
stępowania chorób towarzyszących. W prewencji oraz monitorowaniu chorób układu sercowo-naczyniowego istotne może się 
okazać wykrywanie subklinicznych zmian w układzie krążenia, w tym dysfunkcji śródbłonka i nadmiernej sztywności tętnic. 
Cel: Celem badania była ocena częstości występowania dysfunkcji śródbłonka wśród pacjentów zakażonych HIV oraz znale-
zienie czynników wpływających na pojawienie się dysfunkcji śródbłonka i wpływających na sztywność tętnic.
Metody: Do badania włączono 37 dorosłych chorych z rozpoznanym zakażeniem HIV, bez względu na fakt i rodzaj prowa-
dzonej cART. Kryteria wyłączenia obejmowały: kobiety w ciąży lub karmiące piersią, cART przerwaną krócej niż 6 miesięcy 
przed włączeniem do badania oraz pacjentów z nowotworami niezwiązanymi z zakażeniem HIV. U każdego chorego wyko-
nano badanie oceniające obwodową tonometrię tętniczą reaktywnej hiperemii przy użyciu urządzenia Endo-PAT2000 firmy 
ITAMAR®. Metoda ta pozwalała na czynnościową ocenę funkcji śródbłonka i sztywności tętnic.
Wyniki: Do końcowej analizy włączono 37 osób. Mediana wieku chorych wynosiła 38 lat (32–45 lat), 89,2% całej badanej 
grupy stanowili mężczyźni. Dysfunkcję śródbłonka stwierdzono u 13 (35,1%) osób zakażonych HIV. Uwzględniając dane 
demograficzne, kliniczne, wyniki badań laboratoryjnych oraz terapię lekami kardiologicznymi, nie wykazano istotnych różnic 
między osobami z dysfunkcją śródbłonka i bez niej. Wyjątek stanowiła jedynie liczba płytek krwi, która była istotnie statystycz-
nie niższa u pacjentów z dysfunkcją śródbłonka w porównaniu z pozostałymi chorymi (174 [119–193] vs. 222 [168–266]; 
p = 0,03). Żaden z parametrów demograficznych i klinicznych nie okazał się niezależnym predyktorem wystąpienia dysfunkcji 
śródbłonka w grupie chorych zakażonych HIV. Podobnie nie wykazano korelacji między czynnikami związanymi z zakaże-
niem HIV oraz stosowaną przewlekle farmakoterapią a ryzykiem wystąpienia dysfunkcji śródbłonka. Zaobserwowano istotny 
statystycznie związek między sztywnością tętnic a wiekiem pacjenta (rs = 0,53; p < 0,001), liczbą czerwonych krwinek 
(rs = –0,39; p = 0,018) i liczbą płytek krwi (rs = 0,42; p = 0,009). Biorąc pod uwagę sztywność tętnic, wykazano, że jest 
ona odwrotnie proporcjonalna do liczby kopii wirusa identyfikowanej u poszczególnych chorych (rs = –0,39; p = 0,0018). 
W porównaniu z chorymi bez cART, chorzy poddani cART charakteryzowali się wyższą sztywnością naczyń (10 [0–15] 
vs. –5 [–10–3]; p = 0,014). 
Wnioski: Niniejsze badanie pokazało, że dysfunkcja śródbłonka jest częstym zjawiskiem występującym wśród chorych zaka-
żonych HIV. Brakuje czynników wpływających bezpośrednio na zaburzenie funkcji śródbłonka w tej grupie osób. Komplek-
sowa terapia antyretrowirusowa może mieć działanie negatywne, zwiększające sztywność tętnic. W związku z pilotażowym 
charakterem badania, będzie prowadzona dalsza obserwacja już włączonych pacjentów i rekrutacja nowych. Może to pomóc 
w ustalenia parametrów, które mogą wskazać osoby o podwyższonym ryzyku sercowo-naczyniowym.
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